Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Same-day regimens (SaDs) are on a par with specific-dose regimens (SpDs) with regard to bowel cleanliness, cecal intubation rate (CIR) and adenoma detection rate (ADR), results of a recent meta-analysis have shown. However, SaDs appear to be better than SpDs in preparation quality with bisacodyl.
Factors such as Barret’s oesophagus (BE) length, presence of low-grade dysplasia (LGD) and nodularity increase the risk of progression from nondysplastic (ND)BE or LGD to high-grade dysplasia or oesophageal adenocarcinoma, a study has found.
Aerobic exercise, at doses reaching 300 minutes per week, appear to be effective at improving health-related quality of life (HRQoL) in survivors of stage I–III colon cancer, a recent study has shown.
Depression appears to be a stronger predictor of absenteeism than symptom severity in patients with chronic constipation, suggests a study, adding that depression may partly contribute to the indirect costs of chronic constipation.
False over- and understaging seems to be common with the use of endoscopic ultrasound (EUS) to stage Barrett’s oesophagus (BE) patients with early neoplasia and dysplasia, a recent meta-analysis has shown.
In patients with gallbladder cancer (GBC), reducing and controlling inflammation, as well as targeting relevant pathways, may improve patient outcomes and survival, according to a recent study.
Cognitive behavioural therapy appears to be effective in reducing supragastric belching and improving quality of life, such as in daily and social activities, a recent study has shown.
Special Reports
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
In this issue of MIMS Gastroenterology Supplement, we bring you clinical updates related to hepatitis B, and also a symposium highlight in conjunction with the launch of tenofovir disoproxil fumarate (Ricovir®; Mylan Laboratories) in Malaysia.
Last August, the article 'Role of General Practitioners in Early Detection of Inflammatory Bowel Disease' highlighted proper screening and early specialist referral by the general practitioner (GP) as vital components in reducing the burden of inflammatory bowel disease (IBD). This year, the focus is on the role of GPs in co-managing a patient with IBD at the follow-up phase.
Nonalcoholic fatty liver disease (NAFLD), including simple steatosis and nonalcoholic steatohepatitis (NASH), is widely considered as the liver manifestation of the metabolic syndrome. It is a major cause of liver disease worldwide and its prevalence is expected to rise in tandem with the rising prevalence of obesity and diabetes mellitus. Recently, MIMS Doctor spoke to Associate Professor Dr Wah Kheong Chan, a Consultant Physician and Gastroenterologist at the University of Malaya Medical Centre and University of Malaya Specialist Centre, to provide an update on NAFLD, with a particular emphasis on the use of silymarin for the treatment of NASH. Here are the highlights from the interview.
Constipation is a common disorder which adversely affects the wellbeing and quality of life of patients.1 Recently, MIMS Doctor spoke to Associate Prof Dr Raja Affendi Raja Ali on the landscape of constipation in Malaysia, emphasizing on effective and early management of the condition.
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
At the recent Asian Pacific Digestive Week (APDW) 2016 held in Kobe, Japan, three prominent international experts shared their views on gastroesophageal reflux disease (GERD) and the challenges of its management.
Conference Reports
A weekly dose escalation of regorafenib was superior to starting with the standard dose of 160 mg/day for patients with refractory metastatic colorectal cancer (mCRC), according to the ReDOS* trial presented at the ASCO GI Cancers Symposium 2018.
Patients with inflammatory bowel disease (IBD) who had primary nonresponse ─ or inadequate response to the initial loading doses ─ to an anti-tumour necrosis factor (TNF) agent were less likely to respond to second-line biologics compared with those who had secondary loss of response (LOR) or intolerance to the primary therapy, according to a systematic review and meta-analysis presented at the Crohn's & Colitis Congress (CCC) 2018 held recently in Las Vegas, Nevada, US.
Studies demonstrate conflicting findings on impact of obesity on treatment response, outcomes in IBD
Obesity does not appear to have a significant influence on treatment response and clinical outcomes in patients with inflammatory bowel disease (IBD), according to two studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Use of the gut-selective anti-integrin monoclonal antibody vedolizumab was associated with favourable treatment outcomes in patients with inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease, according to studies presented at the 2018 Crohn’s & Colitis Congress (CCC).
Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.
Rifaximin, an antibiotic that has been approved for treating IBS-D*, may also benefit patients with Crohn's disease (CD), suggests a study presented at the Crohn's & Colitis Congress (CCC) 2018.
Using the JAK* inhibitor tofacitinib as induction therapy for Crohn’s disease (CD) can promote disease remission in certain patients selected based on baseline endoscopic evidence of inflammation, according to a post hoc analysis presented at the recent Crohn's & Colitis Congress (CCC) 2018, Las Vegas, Nevada, US.
Multimedia
.png)
